ReviewBiogerontology2026
Kaempferol as an ovarian aging-modulatory flavonol.
Review in Biogerontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kaempferol (KMP) is a dietary compound found in a wide range of foods. The therapeutic capabilities of these foods are associated with the phenolic compounds present in their structures, particularly their antioxidant activity. Remarkable medical care areas linked to KMP include pain relief, anti-aging, antiallergic, anticancer, antidiabetic, anti-inflammatory, antioxidant, antipyretic, central nervous system regulation, wound healing, and hepatoprotective characteristics. KMP has attracted considerable attention in the examination of its possible roles in dealing with a range of age-related diseases. These conditions include cardiovascular diseases (CVDs), immunoinflammatory diseases, neurodegenerative diseases (NDs), and cancer. It can delay oocyte aging, thereby enhancing the subsequent embryonic growth cascade. Delaying oocyte aging is mainly accomplished by reducing apoptosis and reactive oxygen species (ROS) levels. Furthermore, KMP has antioxidant effects on age-related diminished ovarian reserve (AR-DOR) by reducing HSP90 expression, thereby boosting NRF2 expression. KMP treatment influences multiple processes in aging oocytes, including peroxisome function, oxidative stress, cAMP signaling, TNF signaling, and gap junction pathways. Additionally, KMP improved negative pregnancy outcomes associated with fertilized aged oocytes.
Indexed as
Identifiers
42257891What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.